Search

Your search keyword '"Chen, Yi-Bin"' showing total 1,472 results

Search Constraints

Start Over You searched for: Author "Chen, Yi-Bin" Remove constraint Author: "Chen, Yi-Bin"
1,472 results on '"Chen, Yi-Bin"'

Search Results

4. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

6. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

8. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

9. Third-party fecal microbiota transplantation for high-risk treatment-naïve acute GVHD of the lower GI tract

10. A Day 14 Endpoint for Acute GVHD Clinical Trials

12. Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD+ acute myeloid leukemia

13. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies

14. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year

17. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

18. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

19. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma

20. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

21. A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

22. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease

23. Effective treatment of low-risk acute GVHD with itacitinib monotherapy

27. Chimeric antigen receptor T‐cell therapy in secondary central nervous system lymphoma: A multicenter analysis

28. CAR T Cells in Primary and Secondary CNS Lymphoma (S27.003)

29. Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma

30. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

31. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)

32. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

35. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

36. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial

38. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial

39. Allogeneic B cell immunomodulatory therapy in amyotrophic lateral sclerosis.

43. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

45. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

46. Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis

47. Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells

49. HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia

50. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

Catalog

Books, media, physical & digital resources